MedTrace Logo

Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)

NCT04537780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-09-03

No results posted yet for this study

Summary

the current study is to evaluate the efficacy and safety of Montelukast in the treatment of patients with non-alcoholic steatohepatitis (NASH).

Conditions

  • Non Alcoholic Steatohepatitis

Interventions

OTHER

Placebo

Placebo tabled every day

DRUG

Montelukast

Montelukast 10 mg daily at bed time.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Tarek M Mostafa, Ass. Prof. · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-20
Primary Completion
2020-08-30
Completion
2020-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04537780 on ClinicalTrials.gov